Aventus Thrombectomy System Pulmonary Embolism Clinical Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05907564 |
Recruitment Status :
Recruiting
First Posted : June 18, 2023
Last Update Posted : April 4, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pulmonary Embolism Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases | Device: Thrombectomy | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluate the Safety and Efficacy of the Aventus Thrombectomy System for Aspiration Thrombectomy in Subjects With Acute Pulmonary Embolism |
Actual Study Start Date : | September 20, 2023 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | March 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Single Arm
Device: Aventus Thrombectomy System
|
Device: Thrombectomy
Use of Aventus Thrombectomy System to treat pulmonary embolism |
- Change in RV/LV Ratio [ Time Frame: From Baseline to 48 hours ]Change in RV/LV Ratio per CTA
- Major Adverse Event Rate [ Time Frame: From Index Procedure to 48 hours ]Composite of device related MAEs including death, major bleed, clinical deterioration, pulmonary vascular injury, and cardiac injury
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 and ≤ 80 years
- Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures
- Subject is willing and able to comply with all protocol required follow-up visits
- PE symptom(s) duration ≤ 14 days from index procedure
- PE diagnosis ≤ 48 hours prior to index procedure
- CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery based on Investigator determination)
- CTA evidence of dilated RV with an RV/LV ratio of ≥ 0.9 at baseline based on Investigator determination
- Systolic blood pressure ≥ 90 mmHg without need for vasopressors (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with intravenous fluids prior to index procedure)
- Stable heart rate < 130 BPM prior to index procedure
- Subject is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment
Exclusion Criteria:
- Prior PE ≤ 180 days from index procedure
- Current hospitalization for other condition(s)
- Thrombolytic use ≤ 14 days of baseline CTA
- Pulmonary hypertension with peak pulmonary artery systolic pressure > 70 mmHg by right heart catheterization
- FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%
- Hematocrit < 28% within 6 hours of index procedure
- Platelets < 100,000/μL
- Serum creatinine > 1.8 mg/dL
- International normalized ratio (INR) > 3
- Presence of intracardiac lead in the right ventricle or right atrium placed < 180 days prior to index procedure
- Cardiovascular or pulmonary surgery ≤ 7 days prior to index procedure
- Actively progressing cancer treated by chemotherapeutics
- Known bleeding diathesis or coagulation disorder
- Left bundle branch block
- History of severe or chronic pulmonary arterial hypertension
- History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
- History of uncompensated heart failure
- History of underlying lung disease that is oxygen dependent
- History of chest irradiation
- History of heparin-induced thrombocytopenia (HIT)
- Any contraindication to systemic or therapeutic doses of heparin or anticoagulants
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
- Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for aspiration thrombectomy intervention such as the inability to navigate to target location, predominantly chronic clot or non-clot embolus
- Life expectancy of < 90 days, as determined by Investigator
- Female who is pregnant or nursing
- Current participation in another investigational drug or device treatment study that has not reached the primary endpoint or the Investigator feels would impact their ability to participate in this clinical trial
- Subject has known residual Iliac Deep Vein Thrombosis (DVT), Inferior Vena Cava (IVC) clot or clot in transit (right atrium and/or right ventricular)
- Subject on extracorporeal membrane oxygenation (ECMO)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05907564
Contact: Marc Penna | 978-760-0311 | clinical@inquismedical.com |
United States, Arizona | |
Honor Health | Recruiting |
Scottsdale, Arizona, United States, 85258 | |
United States, California | |
MemorialCare | Recruiting |
Long Beach, California, United States, 90806 | |
United States, District of Columbia | |
Medstar | Recruiting |
Washington, District of Columbia, United States, 20010 | |
United States, Illinois | |
Northwestern University | Recruiting |
Chicago, Illinois, United States, 60611 | |
Alexian Brothers Medical Center | Recruiting |
Elk Grove Village, Illinois, United States, 60007 | |
United States, Indiana | |
Ascension St. Vincent | Recruiting |
Indianapolis, Indiana, United States, 46260 | |
United States, Michigan | |
Ascension Providence | Recruiting |
Southfield, Michigan, United States, 48075 | |
United States, Minnesota | |
CentraCare Heart and Vascular | Recruiting |
Saint Cloud, Minnesota, United States, 56303 | |
United States, New Jersey | |
Hackensack University Medical Center | Recruiting |
Hackensack, New Jersey, United States, 07601 | |
Holy Name Medical Center | Recruiting |
Teaneck, New Jersey, United States, 07666 | |
United States, Ohio | |
University Hospitals | Recruiting |
Cleveland, Ohio, United States, 44106 | |
OhioHealth Research Institute | Recruiting |
Columbus, Ohio, United States, 43214 | |
ProMedica - Jobst Vascular | Recruiting |
Toledo, Ohio, United States, 43606 | |
United States, Oklahoma | |
Ascension St. John | Recruiting |
Tulsa, Oklahoma, United States, 74006 | |
United States, Tennessee | |
Centennial Medical Center (HCA) | Recruiting |
Nashville, Tennessee, United States, 37203 | |
United States, Texas | |
Ascension Seton | Recruiting |
Austin, Texas, United States, 78705 |
Principal Investigator: | Jun Li, MD | University Hospitals | |
Principal Investigator: | Saher Sabri, MD | MedStar Health |
Responsible Party: | Inquis Medical, Inc. |
ClinicalTrials.gov Identifier: | NCT05907564 |
Other Study ID Numbers: |
CT-0001 |
First Posted: | June 18, 2023 Key Record Dates |
Last Update Posted: | April 4, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Pulmonary Embolism Clot Thromboembolism Thrombectomy Right Heart Strain |
Lung Diseases Pulmonary Embolism Respiratory Tract Diseases Cardiovascular Diseases |
Thrombosis Embolism Vascular Diseases Embolism and Thrombosis |